Korean pharmaceutical company will take part in BIO USA
South Korea’s JW Pharmaceutical announced on June 7 that it would take part in the 2022 BIO International Convention, which will take place in San Diego next week.
The Seoul-based company said that it would take advantage of the BIO one-on-one partnering system to seek opportunities of forging an alliance with global pharmaceutical giants.
The partnering system is a platform offered during the 2022 BIO International Convention through behind-the-scenes meetings with senior biotech executives, business development leaders, and investors.
In particular, JW Pharmaceutical strives to find partners to work on its two promising drug candidates of URC102 and JW2286.
The former is a novel inhibitor of human uric acid transporter 1 and has gone through clinical development to treat patients with gout.
The latter is a new first-in-class drug candidate that targets STAT3 involved in cancerous cell growth, proliferation, and drug tolerance.
JW Pharmaceutical is also scheduled to introduce its other drug candidate for hair loss treatment, dubbed JW0061.
“We will carry out discussions on candidates for customized drugs for technological partnership. Global pharmaceutical firms and investors show big interest in our research capability,” a JW Pharmaceutical official said.
The BIO International Convention, otherwise dubbed the BIO USA, is an annual event that attracts more than 15,000 biotechnology and pharmaceutical leaders from across the world.
The convention has expanded its horizon to such areas as drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy.
This year’s event will be hosted in San Diego from July 13 through July 16. It will mark the first offline event in three years due to the novel coronavirus.
It is organized by Biotechnology Innovation Organization (BIO), the world’s largest advocacy association representing biotechnology groups and research institutions.